

PHARMACEUTICAL 2022

## Clovis Oncology Inc. Rank 415 of 466









PHARMACEUTICAL 2022



Clovis Oncology Inc. Rank 415 of 466

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 188% points.

The company's Economic Capital Ratio, given in the ranking table, is -121%, being 199% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	198,087
Cost of Goods Sold	0
Intangible Assets	123,445
Liabilities, Current	125,214
Liabilities, Non-Current	0
Other Assets	144,747
Other Compr. Net Income	874
Other Expenses	59,118
Other Liabilities	626,459
Other Net Income	-39,161
Other Revenues	148,757
Property and Equipment	6,554
Research and Development	186,602
Selling, General and Administrative Expense	128,400

Output Variable	Value in 1000 USD
Assets	472,833
Liabilities	751,673
Expenses	374,120
Revenues	148,757
Stockholders Equity	-278,840
Net Income	-264,524
Comprehensive Net Income	-264,087
Economic Capital Ratio	-121%

